SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.


EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

LEAVE THIS BLANK

By selecting this, I agree to receive emails from celltelligence.com.

Already have an account? Log in here
RETURN TO HOME
$0
Allogeneic, CAR-T, CD19, CD22, Dual/triple agonist

Cellectis to Provide Updates of All Clinical Programs in 2023; Company to Advance FAP-Targeting UCART Program in Solid Tumors into the Clinic; Precision Actively Seeking Partners to Advance Azer-cel and PBCAR19B; Cellectis’s and Precision’s Q2 2023 Earnings Call Summary

Here is a brief preview of this blast: On Friday, August 4, Cellectis held its Q2 2023 earnings call (press release) highlighting anticipated updates for the clinical programs of UCART22 (allogeneic CD22 CAR-T), UCART20x22 (allogeneic CD20xCD22 CAR-T) and UCART123 (allogeneic CD123 CAR-T) later in 2023. On the same day, Precision reported its Q2 2023 earnings call (press release) reiterating the receipt of final Type B meeting minutes from the FDA providing clarity on the potential registrational pathway of its lead asset azer-cel (PBCAR0191; allogeneic CD19 CAR-T), and the active discussions with potential partners for the development of its cell therapy assets. Below, Celltelligence provides insights on Cellectis’s updates of its UCAR-T assets, while discussing Precision’s active search for partnerships and azer-cel’s potential in LBCL.

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.